XBI S&P Biotech SPDR

$67.91 $-2.23 (-3.18%)
Overall

XBI Stock Analysis Overview

What this means: S&P Biotech SPDR (XBI) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives XBI a rank of 15. Our methodology considers analysis of the company's financial situation and how it has traded recently. XBI rank of 15 means that it ranks below 85% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

XBI Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

XBI Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

XBI Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

XBI Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

XBI Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

XBI Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

XBI Stock Analysis Overview

What this means: S&P Biotech SPDR (XBI) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives XBI a rank of 15. Our methodology considers analysis of the company's financial situation and how it has traded recently. XBI rank of 15 means that it ranks below 85% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full XBI report

XBI Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

XBI Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

XBI Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

XBI Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

XBI Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

XBI Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

S&P Biotech SPDR (XBI) Analyst Forecast

XBI Price, Volume, Earnings, and Dividend Date

  • Last Price $67.91
  • Previous Close $70.14
  • Change $-2.23
  • Open $69.13
  • Volume 4,893,167
  • Avg. Volume (100-day) 14,599,304
  • Market Cap 5,307,166,500
  • Days Range 67.15 - 69.47
  • 52-week Range 61.78 - 141.5
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS
  • Earnings Date
  • Sector
  • Industry
  • Avg. Analyst Rec. Premium
  • Beta 1.523
  • PEG Ratio

S&P Biotech SPDR (XBI) Company Description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

S&P Biotech SPDR (XBI) Stock Chart

My Watchlists

Follow Your Favorite Stocks